{
    "clinical_study": {
        "@rank": "161507", 
        "arm_group": [
            {
                "arm_group_label": "Thalidomide plus HD-Dexmamethasone", 
                "arm_group_type": "Experimental", 
                "description": "Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days"
            }, 
            {
                "arm_group_label": "Dexamethasone", 
                "arm_group_type": "Active Comparator", 
                "description": "Dexamethasone 40 mg per day, 4 consecutive days"
            }
        ], 
        "brief_summary": {
            "textblock": "The project was undertaking by Qilu Hospital of Shandong University in China. In order to\n      report the efficacy and safety of thalidomide combining with high-dose dexamethasone for the\n      treatment of adults with primary immune thrombocytopenia (ITP), compared to conventional\n      high-dose dexamethasone mono-therapy."
        }, 
        "brief_title": "High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP", 
        "condition": "Immune Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "The investigators are undertaking a multicenter, randomized controlled trial of 200 primary\n      ITP adult patients from 5 medical centers in China. One part of the participants are\n      randomly selected to receive Thalidomide (given at a dose of 150mg for 15 consecutive days),\n      combining with dexamethasone (given intravenously at a dose of 40 mg per day for 4 days, the\n      others are selected to receive high-dose of dexamethasone treatment (given intravenously at\n      a dose of 40 mg daily for 4 days).\n\n      Platelet count, bleeding and other symptoms were evaluated before and after treatment.\n      Adverse events are also recorded throughout the study. In order to report the efficacy and\n      safety of thalidomide combining with high-dose dexamethasone therapy compared to high-dose\n      dexamethasone for the treatment of adults with ITP."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022newly diagnosed ITP patients need of treatment(s) to minimize the risk of clinically\n             significant bleeding primary ITP confirmed by excluding other supervened causes of\n             thrombocytopenia\n\n        Exclusion Criteria:\n\n          -  \u2022pregnancy hypertension cardiovascular disease diabetes liver and kidney function\n             impairment hepatitis C virus, HIV, HBsAg seropositive status patients with systemic\n             lupus erythematosus and/or antiphospholipid syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01976195", 
            "org_study_id": "ITP-Thalidomide"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Thalidomide plus HD-Dexmamethasone", 
                    "Dexamethasone"
                ], 
                "description": "Dexamethasone 40 mg per day, 4 consecutive days", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Dexamethasone"
            }, 
            {
                "arm_group_label": "Thalidomide plus HD-Dexmamethasone", 
                "description": "Thalidomide 150mg per day, 15 consecutive days", 
                "intervention_name": "Thalidomide", 
                "intervention_type": "Drug", 
                "other_name": "Thalidomide"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Thalidomide", 
            "Dexamethasone", 
            "ITP"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "location": {
            "contact": {
                "email": "houming@medmail.com.cn", 
                "last_name": "Ming Hou"
            }, 
            "facility": {
                "address": {
                    "city": "Jinan", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "250012"
                }, 
                "name": "Qilu hospital, Shandong University"
            }, 
            "investigator": {
                "last_name": "Ming Hou", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label, Randomized Multicenter Investigation of High-dose Dexamethasone Combining Thalidomide Versus High-dose Dexamethasone Mono-therapy for Management of Newly-diagnosed Immune Thrombocytopenia", 
        "overall_contact": {
            "email": "houming@medmail.com.cn", 
            "last_name": "Ming Hou, Doctor"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "People's Republic of China: National Health and Family Planning Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "R. A response (R) was defined as a sustained (\u2265 3 months) platelet count \u2265 30\u00d710^9/L without recurrence of thrombocytopenia", 
            "measure": "Evaluation of platelet response", 
            "safety_issue": "Yes", 
            "time_frame": "Newly diagnosed ITP in 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01976195"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong University", 
            "investigator_full_name": "Ming Hou", 
            "investigator_title": "Professor and Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Shandong University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Anhui Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The First Affiliated Hospital of Dalian Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shenzhen Second People's Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Shandong University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}